- Home
- ZLAB vs NVAX Comparison
ZLAB vs NVAX Comparison
Compare ZLAB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- NVAX
- Stock Information
- Founded
- ZLAB 2013
- NVAX 1987
- Country
- ZLAB China
- NVAX United States
- Employees
- ZLAB N/A
- NVAX N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZLAB Health Care
- NVAX Health Care
- Exchange
- ZLAB Nasdaq
- NVAX Nasdaq
- Market Cap
- ZLAB 3.4B
- NVAX 1.3B
- IPO Year
- ZLAB 2017
- NVAX 1995
- Fundamental
- Price
- ZLAB $32.30
- NVAX $8.56
- Analyst Decision
- ZLAB Buy
- NVAX Buy
- Analyst Count
- ZLAB 6
- NVAX 7
- Target Price
- ZLAB $57.22
- NVAX $14.29
- AVG Volume (30 Days)
- ZLAB 831.7K
- NVAX 6.8M
- Earning Date
- ZLAB 11-11-2025
- NVAX 11-11-2025
- Dividend Yield
- ZLAB N/A
- NVAX N/A
- EPS Growth
- ZLAB N/A
- NVAX N/A
- EPS
- ZLAB N/A
- NVAX 2.54
- Revenue
- ZLAB $427,799,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- ZLAB $42.62
- NVAX $61.69
- Revenue Next Year
- ZLAB $55.12
- NVAX N/A
- P/E Ratio
- ZLAB N/A
- NVAX $3.37
- Revenue Growth
- ZLAB 32.56
- NVAX 9.22
- 52 Week Low
- ZLAB $20.17
- NVAX $5.01
- 52 Week High
- ZLAB $44.34
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- ZLAB 47.53
- NVAX 59.53
- Support Level
- ZLAB $26.67
- NVAX $7.83
- Resistance Level
- ZLAB $33.06
- NVAX $8.31
- Average True Range (ATR)
- ZLAB 1.38
- NVAX 0.37
- MACD
- ZLAB 0.15
- NVAX 0.04
- Stochastic Oscillator
- ZLAB 77.14
- NVAX 92.36
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.